Fukuda Denshi Co., Ltd. (6960.T)
ValueMarkers Composite Index
29% below intrinsic value ($100)
Fukuda Denshi Co., Ltd. (6960.T) — VMCI valuation read
Composite valuation read on 6960.T: VMCI 67/100 against a Healthcare sector median of 50. The 17-point above-median print is the headline number for Fukuda Denshi Co., Ltd., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for 6960.T: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on 6960.T: 6960.T trades at 23.0x earnings, 28% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -1.5x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
6960.T rose 0.1% over the trailing 7 days, with a -21.9% read on a 30-day basis.
Fukuda Denshi Co., Ltd. engages in manufacture and sale of medical instruments in Japan and internationally. It offers resting electrocardiograph products; data management software; stress test products; and patient monitoring systems, including central and bedside monitors, transmitters, and central viewer workstations; and vascular screening systems. The company was founded in 1939 and is based in Tokyo, Japan.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.